AgeneBio to Speak at ASENT 2018 Annual Meeting

Emerging Therapeutics Focus on Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief Scientific Officer, and Krieger-Eisenhower Professor of Psychological and Brain Sciences at Johns Hopkins University, Michela…

AgeneBio Founder Michela Gallagher to Speak at 2018 NIH Alzheimer’s Research Summit

Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief Scientific Officer, HOPE4MCI Principal Investigator, and Krieger-Eisenhower Professor of Psychological and Brain Sciences at Johns…